CSL Limited has announced its full-year results for the 2024/2025 financial year, reporting a net profit after tax of $3.3 billion. This is a profit increase of 14% at constant currency (CC)² versus the previous year and thus exceeds the forecasts for the 2025 financial year.
Dr. Paul McKenzie, CSL’s Chief Executive Officer and Managing Director said, “I am pleased to report another on-target result for the 2025 financial year, led by CSL Behring and continued strong demand for our life-saving plasma therapies.
Read about our CSL 2024/2025 Financial Results as well as the full ASX announcement including operational highlights and outlook on CSL.com.
1All figures are expressed in US dollars unless otherwise stated.
2 Constant currency (CC) removes the impact of exchange rate movements, facilitating comparability of operational performance. For further detail please refer to CSL’s Financial Statements for the Full Year ended June 2024 (Directors’ Report).
